Toggle Nav

Lenvatinib (E7080)

In stock
Catalog No.
A2174
VEGFR inhibitor
Grouped product items
SizePriceStock Qty
10mM (in 1mL DMSO)
$75.00
In stock
5mg
$70.00
In stock
25mg
$300.00
In stock
100mg
$800.00
In stock

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

Background

Lenvatinib (E7080) is an inhibitor of multiple RTK with IC50 values of 22nM, 4nM, 5.2nM, 39nM and 35nM on VEGFR-1, VEGFR-2, VEGFR-3, PDGFRβ and RET, respectively [1].

Lenvatinib is presently under investigation both as monotherapy and in combination with cytotoxic agents for multiple types of solid tumor, including thyroid carcinoma and hepatocellular carcinoma (in Phase III trials), and melanoma, renal carcinoma, non-small cell lung carcinoma, glioblastoma multiforme, and ovarian and endometrial carcinoma (Phase I and II trials) [1].

When used as an inhibitor of RET kinase, Lenvatinib cause growth inhibition in TPC-1 cells and LC-2/ad cells. The GI50 values are 27nM and 48nM. It is also reported that Lenvatinib can inhibit RET (rearranged during transfection) gene fusion kinases, and inhibit oncogenic signaling of RET gene fusions. Lenvatinib has been demonstrated to exert antitumor activities in RET gene fusion-driven tumor models [2].

References:
[1] Neda Stjepanovic, Jaume Capdevila. Multikinase inhibitors in the treatment

of thyroid cancer: specific role of lenvatinib. Biologics: Targets and Therapy. 2014 (8): 129-139.

[2] Kiyoshi Okamoto, Kotaro Kodama, Kazuma Takase, Naoko Hata Sugi, Yuji Yamamoto, Masao Iwata, Akihiko Tsuruoka. Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models. Cancer Letters. 2013 July(340):97-103.

Chemical Properties

StorageStore at -20°C
M.Wt426.85
Cas No.417716-92-8
FormulaC21H19ClN4O4
Solubility≥21.35mg/mL in DMSO
Chemical Name4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxyquinoline-6-carboxamide
SDFDownload SDF
Canonical SMILESCOC1=CC2=NC=CC(=C2C=C1C(=O)N)OC3=CC(=C(C=C3)NC(=O)NC4CC4)Cl
Shipping ConditionEvaluation sample solution : ship with blue ice.All other available size: ship with RT , or blue ice upon request
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.

Protocol

Cell experiment [1]:

Cell lines

HUVECs

Preparation method

The solubility of this compound in DMSO is > 21.4 mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below - 20 °C for several months.

Reacting condition

0 ~ 10 μM; 72 hrs

Applications

In HUVECs stimulated with VEGF and VEGF-C, Lenvatinib strongly inhibited VEGF-R2 and VEGF-R3 with the IC50 values of 0.83 nM and 0.36 nM, respectively. In addition, E7080 showed stronger inhibitory activity against VEGF-induced proliferation of HUVECs (IC50 = 2.7 nmol/L) than basic FGF-induced proliferation of HUVECs (IC50 = 410 nM) and PDGF-induced proliferation of L cells (IC50 = 340 nM).

Animal experiment [1]:

Animal models

Nude mice bearing MDA-MB-231 cells

Dosage form

100 mg/kg; p.o.; q.d., for 8 weeks

Applications

In nude mice bearing MDA-MB-231 cells, E7080 significantly inhibited tumor growth, with a RTV value of 0.81 ± 1.00. E7080 also markedly inhibited metastasis to regional lymph nodes and distant lung. In addition, E7080 reduced angiogenesis and lymphangiogenesis within metastatic nodules in lymph nodes of MDA-MB-231 xenograft models.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

[1]. Matsui J, Funahashi Y, Uenaka T, Watanabe T, Tsuruoka A, Asada M. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res. 2008 Sep 1;14(17):5459-65.

Biological Activity

Description Lenvatinib is an inhibitor of multiple RTK with IC50 values of 22 nM, 4 nM, 5.2 nM, 39 nM and 35 nM on VEGFR-1, VEGFR-2, VEGFR-3, PDGFRβ and RET, respectively.
Targets VEGFR-1 VEGFR-2 VEGFR-3 PDGFRβ RET  
IC50 22 nM 4 nM 5.2 nM 39 nM 35 nM  

Quality Control